Intestinal Microenvironment Offers New Framework for Understanding Disorders of Gut–Brain Interaction

For decades, gastroenterologists have managed conditions like irritable bowel syndrome and functional dyspepsia without a clear biological roadmap. A sweeping new review in Gastroenterology is helping to change that by reframing these disorders through a more integrated lens: the intestinal microenvironment.

The paper arrives at a pivotal moment for the field, forming part of the scientific foundation for the upcoming Rome V criteria — the globally recognized framework that will guide the diagnosis and classification of disorders of gut–brain interaction (DGBI) for the next decade.

Co-authored by Houston Methodist Chief of Gastroenterology Dr. Eamonn Quigley — a longtime contributor to the Rome consensus process — and emanating from the work of a panel of experts from across the spectrum of GI health, the paper synthesizes a decade of rapidly expanding research on how diet, the microbiome, the gut barrier, immune activity and neuroendocrine signaling play a role in the pathogenesis of DGBI.

The team's goal was to provide clarity around conditions defined by dysregulated communication between the gastrointestinal tract and central nervous system rather than structural disease.

The result is both a state-of-the-art science update and a practical guidepost for clinicians navigating some of gastroenterology’s most complex patients.

“This was really about stepping back and asking — what are the key drivers across all of these disorders?” Dr. Quigley explains. “We looked at diet, the microbiome, barrier function, immune responses and neuroendocrine signaling as an integrated system, but not in isolation as their integration was a central theme of our work.”

Diet moves to center stage

Among the clearest clinical takeaways: diet is no longer peripheral — it is foundational.

“Diet has emerged as a major factor in symptom development. In many cases, it’s now a fundamental part of management, particularly in irritable bowel syndrome.”

---

Eamonn Quigley, MD

The paper highlights how dietary components — from FODMAPs to fats — interact with gut physiology, microbial metabolism and immune signaling. For practicing clinicians, this reinforces a growing shift toward structured dietary interventions and multidisciplinary care, including routine involvement of dietitians.

At leading centers, that shift is already underway. “When patients present with these disorders, dietary assessment is essential,” Dr. Quigley notes. “It should be part of standard care.”

Microbiome: promise, but not yet precision

If diet is actionable today, the microbiome remains a frontier.

Despite an explosion of research — hundreds of studies over the past decade — the paper underscores a critical limitation: heterogeneity. Patients with DGBI vary widely in symptoms, severity and overlap, making it difficult to define a consistent microbial “signature.”

“There are a lot of data, but also a lot of noise,” says Dr. Quigley. “We know the microbiome is altered, but we don’t yet have a reliable pattern that can diagnose these disorders.”

For clinicians, the implication is clear: microbiome testing is not yet ready for routine diagnostic use. However, emerging approaches — including multi-omics and metabolomics — may eventually provide more clinically meaningful insights, particularly as researchers shift from cataloging organisms to understanding their functional outputs.

Barrier, immunity and the ‘leaky gut’ question

The intestinal barrier — often referred to in lay terms as “leaky gut” — is another area of intense interest. The paper confirms that permeability changes are present in many patients, but translating those findings into clinical tools remains challenging.

“There are clearly alterations in barrier function,” says Dr. Quigley. “But measuring them reliably in humans, in a way that informs care, is still difficult.”

More promising, perhaps, are advances in understanding immune activation. Subtle, localized immune responses — including eosinophil activity and food-triggered reactions detectable only with advanced imaging — are reshaping how clinicians think about symptom generation, with potential implications for targeted dietary elimination strategies and future immune-modulating therapies.

One particularly intriguing insight: gastrointestinal infections may trigger long-term symptoms not just through inflammation, but by inducing new food sensitivities.

“That concept — loss of tolerance after infection — opens up an entirely new way of thinking about post-infection IBS,” Dr. Quigley says.

Toward a more integrated model of care

Ultimately, the paper does not offer a diagnostic breakthrough. Instead, it provides something arguably more valuable: a framework.

By emphasizing the interplay between diet, microbes, immunity and neural signaling, the review encourages clinicians to move beyond siloed thinking and toward a systems-based approach to care.

For Dr. Quigley, who has contributed to multiple iterations of the Rome deliberations over decades, the work reflects both continuity and evolution in the field.

“These disorders have always been complex,” he says. “What’s changed is that we’re now beginning to understand the biology behind that complexity — and that’s what will ultimately lead to better treatments.”

For gastroenterologists, the message is pragmatic: incorporate diet, stay cautious on emerging diagnostics, and recognize that the future of gut–brain disorders will be defined not by a single pathway, but by how well we understand — and treat — the system as a whole.